185 related articles for article (PubMed ID: 15056649)
41. In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.
Eliopoulos GM; Ferraro MJ; Wennersten CB; Moellering RC
Antimicrob Agents Chemother; 2005 Jul; 49(7):3034-9. PubMed ID: 15980394
[TBL] [Abstract][Full Text] [Related]
42. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.
Streit JM; Jones RN; Sader HS
J Antimicrob Chemother; 2004 Apr; 53(4):669-74. PubMed ID: 14985278
[TBL] [Abstract][Full Text] [Related]
43. The post-antibiotic effects of linezolid against Gram-positive pathogens.
Hosgor-Limoncu M; Ermertcan S; Tasli H; Aydemir S
Saudi Med J; 2007 Apr; 28(4):551-4. PubMed ID: 17457476
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and antibacterial activity of novel (un)substituted benzotriazolyl oxazolidinone derivatives.
Dixit PP; Nair PS; Patil VJ; Jain S; Arora SK; Sinha N
Bioorg Med Chem Lett; 2005 Jun; 15(12):3002-5. PubMed ID: 15908210
[TBL] [Abstract][Full Text] [Related]
45. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
Gales AC; Sader HS; Jones RN
Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
[TBL] [Abstract][Full Text] [Related]
46. Antibacterial activity of YC-20, a new oxazolidinone.
Cui Y; Dang Y; Yang Y; Zhang S; Ji R
J Antimicrob Chemother; 2006 Aug; 58(2):452-4. PubMed ID: 16807251
[TBL] [Abstract][Full Text] [Related]
47. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
[TBL] [Abstract][Full Text] [Related]
48. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
49. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
50. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.
Credito K; Lin G; Ednie LM; Appelbaum PC
Antimicrob Agents Chemother; 2004 Oct; 48(10):4033-6. PubMed ID: 15388473
[TBL] [Abstract][Full Text] [Related]
51. Optimizing therapy for vancomycin-resistant enterococci (VRE).
Linden PK
Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and antibacterial activity of some aryloxy/thioaryloxy oxazolidinone derivatives.
Arora V; Salunkhe MM; Sinha N; Sinha RK; Jain S
Bioorg Med Chem Lett; 2004 Sep; 14(18):4647-50. PubMed ID: 15324881
[TBL] [Abstract][Full Text] [Related]
53. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
54. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.
King A; Phillips I; Kaniga K
J Antimicrob Chemother; 2004 May; 53(5):797-803. PubMed ID: 15028667
[TBL] [Abstract][Full Text] [Related]
55. Molecular analysis of streptogramin resistance in enterococci.
Werner G; Klare I; Witte W
Int J Med Microbiol; 2002 Jul; 292(2):81-94. PubMed ID: 12195739
[TBL] [Abstract][Full Text] [Related]
56. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Streit JM; Jones RN; Sader HS; Fritsche TR
Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
[TBL] [Abstract][Full Text] [Related]
57. Antibacterial activity of LCB01-0062, a novel oxazolidinone.
Jung SJ; Yun IN; Park HS; Lee HH; Jeong JW; Kim YZ; Cho YL; Kwak JH
Int J Antimicrob Agents; 2012 Dec; 40(6):539-43. PubMed ID: 23058227
[TBL] [Abstract][Full Text] [Related]
58. [Molecular characterization of vancomycin-resistant enterococci isolates].
Liu YM; Cao B; Wang H; Li BB; Yang CX; Wang QT; Du XL; Li F; Wang SS; Qu SS
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(11):760-3. PubMed ID: 18683685
[TBL] [Abstract][Full Text] [Related]
59. United States resistance surveillance results for linezolid (LEADER Program for 2007).
Jones RN; Ross JE; Castanheira M; Mendes RE
Diagn Microbiol Infect Dis; 2008 Dec; 62(4):416-26. PubMed ID: 19022153
[TBL] [Abstract][Full Text] [Related]
60. New oxazolidinones.
Vara Prasad JV
Curr Opin Microbiol; 2007 Oct; 10(5):454-60. PubMed ID: 17928263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
